Monoclonal antibody reactive with human-origin CETP and method of quantifying human-origin CETP

• US 6,140,474 A
• Filed: 10/31/1997
• Issued: 10/31/2000
• Est. Priority Date: 05/02/1995
• Status: Expired due to Term

• Current Assignee: Japan Tobacco Inc.
• Original Assignee: Japan Tobacco Inc.
• Inventors: Okamoto, Hiroshi, Tamatani, Takuya, Kamada, Masafumi
• Primary Examiner(s): Chan, Christina Y.
• Assistant Examiner(s): LUBET, MARTHA T
• Application Number:
  US08/945,646
• Time in Patent Office: 1,096 Days
• Field of Search: 435/810, 424/133.1, 424/134.1, 424/141.1, 424/146.1, 530/387.3, 530/388.1, 530/391.3, 530/388.85
• US Class Current: 530/388.85
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: C07K 16/18 against material from animals or humans
• CPC Class Codes: C07K 2317/54 F(ab')2
• CPC Class Codes: C07K 2317/55 Fab or Fab'
• CPC Class Codes: Y10S 435/81 Packaged device or kit

Abstract

Monoclonal antibodies which have binding specificity to human CETP (CETP inhibition activity) and which are useful as reagents for purification or quantification of human CETP, and as pharmaceuticals to prevent and/or treat hyperlipidemia or arteriosclerosis are provided. Furthermore, purification and quantification methods of human CETP by using the monoclonal antibodies are also provided.

Claims

1. A hybridoma cell line which secretes an anti-human CETP monoclonal antibody wherein said hybridoma cell line is selected from the group consisting of the cell line deposited under the Accession Number FERM BP-4944 and the cell line deposited under the Accession Number FERM BP-4945.

2. An anti-human CETP monoclonal antibody wherein said monoclonal antibody is secreted by a hybridoma cell line selected from the group consisting of the cell line having a Deposit Accession Number FERM BP-4944 and the cell line having a Deposit Accession Number FERM BP-4945.

3. A recombinant chimeric monoclonal antibody comprising a variable region from the monoclonal antibody of claim 2 and a constant region from a human immunoglobulin.

4. A recombinant humanized monoclonal antibody comprising a part of or the whole of the complementarity determining regions of the hypervariable region from the monoclonal antibody of claim 2, framework regions of the hypervariable region from a human immunoglobulin and a constant region from a human immunoglobulin.

5. An F(ab'"'"')₂ or Fab'"'"' fragment of the monoclonal antibody of claim 2.

6. An immobilized monoclonal antibody or immobilized antibody fragment which is prepared by immobilizing the monoclonal antibody of claim 2 or antibody fragment of claim 5 on an insoluble carrier.

7. The immobilized monoclonal antibody or immobilized antibody fragment of claim 6 wherein said insoluble carrier is selected from the group consisting of a plate, a test tube, a tube, beads, a ball, a filter and a membrane.

8. The immobilized monoclonal antibody or immobilized antibody fragment of claim 6 wherein said insoluble carrier is one used for affinity column chromatography.

9. A labeled monoclonal antibody or labeled antibody fragment which is prepared by labeling the monoclonal antibody of claim 2 or antibody fragment of claim 5 with a labeling substance capable of providing a detectable signal independently or by reaction with another substance.

10. The labeled monoclonal antibody or labeled antibody fragment of claim 9 wherein said labeling substance is selected from the group consisting of an enzyme, a fluorescent material, a chemical luminous material, biotin, avidin and a radioisotope.

11. A kit for immunoassay to detect human CETP comprising the monoclonal antibody of claim 2 or antibody fragment of claim 5.

12. A kit for immunoassay to detect human CETP comprising the labeled monoclonal antibody or labeled antibody fragment of claim 9.

13. A kit for immunoassay to detect human CETP, or separation or purification of human CETP comprising the immobilized monoclonal antibody or immobilized antibody fragment of claim 6.